Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.22

-0.6%

10:15 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (9670)	12/5/2003 5:04:53 PM
From: keokalani'nui	Read Replies (2) of 52153

While we're (still) on the Flu subject, even though it is far away, one might keep in mind crxl's whole-killed (could also describe the shareholders!) program. Over the last 2 years they've proven to themselves perC6 can grow every flu strain and have darn near proven to themselves it would give scalable mfng for millions of doses at a single factory cost of E40mm. Aside from egg allergy and fewer impurities, which I don't take to be serious marketing advantages, they are working to design their system (basically requiring the making of their own medium) to respond to new (or imminent) viral strains much more quickly (don't need to wait around for the eggs) which clearly would be a marketing advantage. Expect it in humans 2005. They claim as short as a 2-year clinical development period. While I'm on the subject, the malaria vaccine program though merely subject to a R&D K with GSK will have a go-no-go based on animal data 1H04. A positive result would look like the announcement of a true joint development collabortaion and would have a big effect on the stock price IMO. Lots of reasons why GSK would like it work. FWIW.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next